Degradation of Androgen Receptor through Small Molecules for Prostate Cancer

Author(s): Raoling Ge, Xi Xu, Pengfei Xu, Lei Li, Zhiyu Li*, Jinlei Bian*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 7 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Prostate cancer is the most common carcinoma among aged males in western countries and more aggressive and lethal castration resistant prostate cancer often occurs after androgen deprivation therapy. The high expression of androgens and androgen receptor is closely related to prostate cancer. Efficient androgen receptor antagonists, such as enzalutamide and ARN-509, could be employed as potent anti-prostate cancer agents. Nevertheless, recent studies have revealed that F876L mutation in androgen receptor converts the action of enzalutamide and ARN-509 from an antagonist to agonist, so that novel strategies are urgent to address this resistance mechanism. In this review, we focus on the discussion about some novel strategies, which targets androgen receptor mainly through the degrading pathway as potential treatments for prostate cancer.

Keywords: Resistance mechanism, androgen receptor, degradation, prostate cancer, small molecules, new strategies.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [652 - 667]
Pages: 16
DOI: 10.2174/1568009617666171107103936
Price: $65

Article Metrics

PDF: 81
HTML: 16
PRC: 1